Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Out

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Human Reproduction (Oxford, England)|June 2, 2001
A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cyclesH J Out, I David, R Ron-El, et al.
Human Reproduction (Oxford, England)|April 30, 1999
A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulationH J Out, S Lindenberg, A L Mikkelsen, et al.
Human Reproduction (Oxford, England)|December 28, 1999
Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulationH J Out, D D Braat, B M Lintsen, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Human Reproduction (Oxford, England)|June 2, 2001
A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cyclesH J Out, I David, R Ron-El, et al.
Human Reproduction (Oxford, England)|April 30, 1999
A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulationH J Out, S Lindenberg, A L Mikkelsen, et al.
Human Reproduction (Oxford, England)|December 28, 1999
Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulationH J Out, D D Braat, B M Lintsen, et al.
Pageof 4